MarketPulse

Soleno Therapeutics

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Soleno Therapeutics Faces Securities Lawsuit Over Undisclosed Drug Safety Risks

$SLNO investors urged to join class action over undisclosed DCCR safety concerns; May 5, 2026 deadline.
SLNOsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

Soleno Therapeutics Faces Securities Lawsuit Over DCCR Safety Disclosures

Securities class action filed against $SLNO alleging false statements about DCCR drug safety. Investors must claim lead plaintiff status by May 5, 2026.
SLNOstock declinesecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Soleno Therapeutics Faces Class Action Over Undisclosed Safety Risks in DCCR Drug

Rosen Law Firm files securities class action against $SLNO for alleged misstatements regarding safety concerns with DCCR drug candidate for Prader-Willi syndrome treatment.
SLNOsecurities class actionlead plaintiff
GlobeNewswire Inc.GlobeNewswire Inc.··Schall Law Firm

Soleno Therapeutics Faces Securities Fraud Lawsuit Over Clinical Trial Disclosures

Schall Law Firm filed securities fraud class action against $SLNO for allegedly concealing safety concerns in Phase 3 DCCR trial. Investors eligible through November 4, 2025.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

Soleno Therapeutics Faces Securities Fraud Probe Over Undisclosed Safety Data

Law firm probing Soleno Therapeutics for allegedly concealing safety data on drug DCCR. Investors must file claims by May 5, 2026.
SLNOstock declinesecurities class action